- Home
- AMSF vs IOVA Comparison
AMSF vs IOVA Comparison
Compare AMSF & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- IOVA
- Stock Information
- Founded
- AMSF 1985
- IOVA 2007
- Country
- AMSF United States
- IOVA United States
- Employees
- AMSF N/A
- IOVA N/A
- Industry
- AMSF Accident &Health Insurance
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMSF Finance
- IOVA Health Care
- Exchange
- AMSF Nasdaq
- IOVA Nasdaq
- Market Cap
- AMSF 869.6M
- IOVA 771.4M
- IPO Year
- AMSF 2005
- IOVA N/A
- Fundamental
- Price
- AMSF $43.50
- IOVA $1.98
- Analyst Decision
- AMSF Buy
- IOVA Buy
- Analyst Count
- AMSF 2
- IOVA 10
- Target Price
- AMSF $59.50
- IOVA $12.22
- AVG Volume (30 Days)
- AMSF 130.4K
- IOVA 11.5M
- Earning Date
- AMSF 07-28-2025
- IOVA 08-07-2025
- Dividend Yield
- AMSF 10.39%
- IOVA N/A
- EPS Growth
- AMSF N/A
- IOVA N/A
- EPS
- AMSF 2.48
- IOVA N/A
- Revenue
- AMSF $301,216,000.00
- IOVA $212,679,000.00
- Revenue This Year
- AMSF $1.69
- IOVA $86.62
- Revenue Next Year
- AMSF $6.54
- IOVA $69.95
- P/E Ratio
- AMSF $17.54
- IOVA N/A
- Revenue Growth
- AMSF N/A
- IOVA 11070.12
- 52 Week Low
- AMSF $42.26
- IOVA $1.64
- 52 Week High
- AMSF $60.24
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- AMSF 29.18
- IOVA 43.44
- Support Level
- AMSF $44.64
- IOVA $1.95
- Resistance Level
- AMSF $44.94
- IOVA $2.47
- Average True Range (ATR)
- AMSF 0.85
- IOVA 0.15
- MACD
- AMSF -0.19
- IOVA 0.05
- Stochastic Oscillator
- AMSF 2.27
- IOVA 35.53
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.